PARIS (Reuters) – Shares in biotech firm Valneva dropped as much as 6.9% on Tuesday after the European Union drug regulator said the firm’s COVID-19 vaccine was under an EU rolling review but it was still awaiting some additional data.
Valneva’s share price has fluctuated sharply in recent weeks on news about the company’s COVID-19 vaccine candidate.
(Reporting by Tassilo Hummel, editing by GV De Clercq)
